The splice variants of vascular endothelial growth factor (VEGF) and their receptors.

Vascular endothelial growth factor (VEGF) is a secreted mitogen highly specific for cultured endothelial cells. In vivo VEGF induces microvascular permeability and plays a central role in both angiogenesis and vasculogenesis. VEGF is a promising target for therapeutic intervention in certain pathological conditions that are angiogenesis dependent, most notably the neovascularisation of growing tumours. Through alternative mRNA splicing, a single gene gives rise to several distinct isoforms of VEGF, which differ in their expression patterns as well as their biochemical and biological properties. Two VEGF receptor tyrosine kinases (VEGFRs) have been identified, VEGFR-1 (Flt-1) and VEGFR-2 (KDR/Flk-1). VEGFR-2 seems to mediate almost all observed endothelial cell responses to VEGF, whereas roles for VEGFR-1 are more elusive. VEGFR-1 might act predominantly as a ligand-binding molecule, sequestering VEGF from VEGFR-2 signalling. Several isoform-specific VEGF receptors exist that modulate VEGF activity. Neuropilin-1 acts as a co-receptor for VEGF(165), enhancing its binding to VEGFR-2 and its bioactivity. Heparan sulphate proteoglycans (HSPGs), as well as binding certain VEGF isoforms, interact with both VEGFR-1 and VEGFR-2. HSPGs have a wide variety of functions, such as the ability to partially restore lost function to damaged VEGF(165) and thereby prolonging its biological activity.

[1]  A. Eichmann,et al.  Ligand-dependent development of the endothelial and hemopoietic lineages from embryonic mesodermal cells expressing vascular endothelial growth factor receptor 2. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[2]  K. Alitalo,et al.  Vascular endothelial growth factor C induces angiogenesis in vivo. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[3]  H. Dvorak,et al.  Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. , 1983, Science.

[4]  S. Soker,et al.  The binding of vascular endothelial growth factor to its receptors is dependent on cell surface-associated heparin-like molecules. , 1992, The Journal of biological chemistry.

[5]  K. Alitalo,et al.  Genomic Organization of the Mouse and Human Genes for Vascular Endothelial Growth Factor B (VEGF-B) and Characterization of a Second Splice Isoform* , 1996, The Journal of Biological Chemistry.

[6]  J. Winer,et al.  Dual regulation of vascular endothelial growth factor bioavailability by genetic and proteolytic mechanisms. , 1992, The Journal of biological chemistry.

[7]  Y. Hirata,et al.  Molecular cloning of a novel vascular endothelial growth factor, VEGF-D. , 1997, Genomics.

[8]  A. N. Corps,et al.  A vascular endothelial growth factor antagonist is produced by the human placenta and released into the maternal circulation. , 1998, Biology of reproduction.

[9]  D. Gospodarowicz,et al.  VEGF receptor subtypes KDR and FLT1 show different sensitivities to heparin and placenta growth factor. , 1994, Growth factors.

[10]  G. Martiny-Baron,et al.  The α-Helical Domain Near the Amino Terminus Is Essential for Dimerization of Vascular Endothelial Growth Factor* , 1998, The Journal of Biological Chemistry.

[11]  T. Sawada,et al.  Prognostic value of vascular endothelial growth factor expression in gastric carcinoma , 1996, Cancer.

[12]  T. Kitsukawa,et al.  Overexpression of a membrane protein, neuropilin, in chimeric mice causes anomalies in the cardiovascular system, nervous system and limbs. , 1995, Development.

[13]  K. Alitalo,et al.  Expression of the fms-like tyrosine kinase 4 gene becomes restricted to lymphatic endothelium during development. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[14]  Mikyoung Park,et al.  The fourth immunoglobulin-like loop in the extracellular domain of FLT-1, a VEGF receptor, includes a major heparin-binding site. , 1999, Biochemical and biophysical research communications.

[15]  B. Li,et al.  Requirements for Binding and Signaling of the Kinase Domain Receptor for Vascular Endothelial Growth Factor* , 1998, The Journal of Biological Chemistry.

[16]  M. Shibuya,et al.  A unique signal transduction from FLT tyrosine kinase, a receptor for vascular endothelial growth factor VEGF. , 1995, Oncogene.

[17]  D. Gospodarowicz,et al.  Transcriptional regulation of vascular endothelial growth factor gene expression in ovarian bovine granulosa cells. , 1993, Growth factors.

[18]  T. Noda,et al.  Flt-1 lacking the tyrosine kinase domain is sufficient for normal development and angiogenesis in mice. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[19]  H. Weich,et al.  A heparin-binding form of placenta growth factor (PlGF-2) is expressed in human umbilical vein endothelial cells and in placenta. , 1993, Growth factors.

[20]  K. Alitalo,et al.  A novel vascular endothelial growth factor, VEGF‐C, is a ligand for the Flt4 (VEGFR‐3) and KDR (VEGFR‐2) receptor tyrosine kinases. , 1996, The EMBO journal.

[21]  D. Connolly,et al.  Vascular permeability factor, an endothelial cell mitogen related to PDGF. , 1989, Science.

[22]  G. Semenza,et al.  Structural and functional analysis of hypoxia-inducible factor 1. , 1997, Kidney international.

[23]  J. Park,et al.  The vascular endothelial growth factor (VEGF) isoforms: differential deposition into the subepithelial extracellular matrix and bioactivity of extracellular matrix-bound VEGF. , 1993, Molecular biology of the cell.

[24]  Georg Breier,et al.  Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo , 1992, Nature.

[25]  P. Welker,et al.  Synthesis, storage, and release of vascular endothelial growth factor/vascular permeability factor (VEGF/VPF) by human mast cells: implications for the biological significance of VEGF206. , 1998, Molecular biology of the cell.

[26]  D. Connolly,et al.  Vascular permeability factor: a tumor-derived polypeptide that induces endothelial cell and monocyte procoagulant activity, and promotes monocyte migration , 1990, The Journal of experimental medicine.

[27]  Atsushi Namiki,et al.  Indirect Angiogenic Cytokines Upregulate VEGF and bFGF Gene Expression in Vascular Smooth Muscle Cells, Whereas Hypoxia Upregulates VEGF Expression Only , 1994 .

[28]  H. Cai,et al.  Cloning and Characterization of Neuropilin-1-Interacting Protein: A PSD-95/Dlg/ZO-1 Domain-Containing Protein That Interacts with the Cytoplasmic Domain of Neuropilin-1 , 1999, The Journal of Neuroscience.

[29]  M. Shibuya,et al.  Vascular endothelial growth factor B (VEGF-B) binds to VEGF receptor-1 and regulates plasminogen activator activity in endothelial cells. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[30]  R. Brace,et al.  Vascular endothelial growth factor gene expression in ovine placenta and fetal membranes. , 1995, American journal of obstetrics and gynecology.

[31]  Lieve Moons,et al.  Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele , 1996, Nature.

[32]  S. Stringer,et al.  Heparan sulphate. , 1997, The international journal of biochemistry & cell biology.

[33]  S. Soker,et al.  Selective binding of VEGF121 to one of the three vascular endothelial growth factor receptors of vascular endothelial cells. , 1996, The Journal of biological chemistry.

[34]  B. Keyt,et al.  Homologous Up-regulation of KDR/Flk-1 Receptor Expression by Vascular Endothelial Growth Factor in Vitro * , 1998, The Journal of Biological Chemistry.

[35]  B. Olffson Vascular endothelial grouth facter B, a novel growth facter for endothelial cells , 1996 .

[36]  J. Winer,et al.  The vascular endothelial growth factor family: identification of a fourth molecular species and characterization of alternative splicing of RNA. , 1991, Molecular endocrinology.

[37]  G. Viglietto,et al.  Isolation of a human placenta cDNA coding for a protein related to the vascular permeability factor. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[38]  K. Alitalo,et al.  Vascular endothelial growth factor is induced in response to transforming growth factor-beta in fibroblastic and epithelial cells. , 1994, The Journal of biological chemistry.

[39]  W. Hendrickson,et al.  A structural superfamily of growth factors containing a cystine knot motif , 1993, Cell.

[40]  I. Zachary Vascular Endothelial Growth Factor: How It Transmits Its Signal , 1998, Nephron Experimental Nephrology.

[41]  H Ueno,et al.  The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor. , 1992, Science.

[42]  M. Tessier-Lavigne,et al.  Neuropilin Is a Receptor for the Axonal Chemorepellent Semaphorin III , 1997, Cell.

[43]  M. Goldberg,et al.  Transcriptional Regulation of the Rat Vascular Endothelial Growth Factor Gene by Hypoxia (*) , 1995, The Journal of Biological Chemistry.

[44]  B. Keyt,et al.  Identification of Vascular Endothelial Growth Factor Determinants for Binding KDR and FLT-1 Receptors , 1996, The Journal of Biological Chemistry.

[45]  P. Pollock,et al.  Cloning and characterization of a novel human gene related to vascular endothelial growth factor. , 1996, Genome research.

[46]  G. Neufeld,et al.  VEGF145, a Secreted Vascular Endothelial Growth Factor Isoform That Binds to Extracellular Matrix* , 1997, The Journal of Biological Chemistry.

[47]  L. Orci,et al.  Vascular endothelial growth factor (VEGF) induces plasminogen activators and plasminogen activator inhibitor-1 in microvascular endothelial cells. , 1991, Biochemical and biophysical research communications.

[48]  K. Alitalo,et al.  Vascular endothelial growth factor (VEGF)‐C synergizes with basic fibroblast growth factor and VEGF in the induction of angiogenesis in vitro and alters endothelial cell extracellular proteolytic activity , 1998, Journal of cellular physiology.

[49]  S. Oliviero,et al.  血小板由来増殖因子/血管内皮増殖因子ファミリーと相関するc‐fos誘導性遺伝子の同定 , 1996 .

[50]  S. Soker,et al.  Neuropilin-1 Mediates Collapsin-1/Semaphorin III Inhibition of Endothelial Cell Motility , 1999, The Journal of cell biology.

[51]  I. Zachary Vascular endothelial growth factor. , 1998, The international journal of biochemistry & cell biology.

[52]  B. Keyt,et al.  Hypoxia-induced paracrine regulation of vascular endothelial growth factor receptor expression. , 1996, The Journal of clinical investigation.

[53]  J. Folkman What is the evidence that tumors are angiogenesis dependent? , 1990, Journal of the National Cancer Institute.

[54]  R. Linhardt,et al.  Identification of a heparin binding peptide on the extracellular domain of the KDR VEGF receptor. , 1997, Growth Factors.

[55]  W. Kaelin,et al.  Negative regulation of hypoxia-inducible genes by the von Hippel-Lindau protein. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[56]  E. Kremmer,et al.  Mapping of the Sites for Ligand Binding and Receptor Dimerization at the Extracellular Domain of the Vascular Endothelial Growth Factor Receptor FLT-1* , 1997, The Journal of Biological Chemistry.

[57]  G. Goodall,et al.  Hypoxic regulation of vascular endothelial growth factor mRNA stability requires the cooperation of multiple RNA elements. , 1999, Molecular biology of the cell.

[58]  J. Stone,et al.  Vascular endothelial growth factor acts as a survival factor for newly formed retinal vessels and has implications for retinopathy of prematurity , 1995, Nature Medicine.

[59]  B. Spiegelman,et al.  Structural requirements for dimerization, glycosylation, secretion, and biological function of VPF/VEGF. , 1995, Biochimica et biophysica acta.

[60]  H. Augustin,et al.  A novel vascular endothelial growth factor encoded by Orf virus, VEGF‐E, mediates angiogenesis via signalling through VEGFR‐2 (KDR) but not VEGFR‐1 (Flt‐1) receptor tyrosine kinases , 1999, The EMBO journal.

[61]  S. Oliviero,et al.  Identification of a c-fos-induced gene that is related to the platelet-derived growth factor/vascular endothelial growth factor family. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[62]  Shay Soker,et al.  Neuropilin-1 Is Expressed by Endothelial and Tumor Cells as an Isoform-Specific Receptor for Vascular Endothelial Growth Factor , 1998, Cell.

[63]  G. Semenza,et al.  Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1 , 1996, Molecular and cellular biology.

[64]  N. Voelkel,et al.  Increased gene expression for VEGF and the VEGF receptors KDR/Flk and Flt in lungs exposed to acute or to chronic hypoxia. Modulation of gene expression by nitric oxide. , 1995, The Journal of clinical investigation.

[65]  K. Alitalo,et al.  A novel vascular endothelial growth factor, VEGF-C, is a ligand for the Flt4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases. , 1996, The EMBO journal.

[66]  M. Shibuya,et al.  Different signal transduction properties of KDR and Flt1, two receptors for vascular endothelial growth factor. , 1994, The Journal of biological chemistry.

[67]  K. Alitalo,et al.  Vascular endothelial growth factor D (VEGF-D) is a ligand for the tyrosine kinases VEGF receptor 2 (Flk1) and VEGF receptor 3 (Flt4). , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[68]  Jianxun Lei,et al.  Identification and characterization of a new splicing variant of vascular endothelial growth factor: VEGF183. , 1998, Biochimica et biophysica acta.

[69]  Charles Eigenbrot,et al.  Crystal Structure at 1.7 Å Resolution of VEGF in Complex with Domain 2 of the Flt-1 Receptor , 1997, Cell.

[70]  Y. Cao,et al.  Placenta growth factor: identification and characterization of a novel isoform generated by RNA alternative splicing. , 1997, Biochemical and biophysical research communications.

[71]  G. Martiny-Baron,et al.  Reversion of deregulated expression of vascular endothelial growth factor in human renal carcinoma cells by von Hippel-Lindau tumor suppressor protein. , 1996, Cancer research.

[72]  C. Goodman,et al.  Neuropilin-2, a Novel Member of the Neuropilin Family, Is a High Affinity Receptor for the Semaphorins Sema E and Sema IV but Not Sema III , 1997, Neuron.

[73]  N. Ferrara,et al.  Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells. , 1989, Biochemical and biophysical research communications.

[74]  Yihai Cao,et al.  Proteolytic processing regulates receptor specificity and activity of VEGF‐C , 1997, The EMBO journal.

[75]  M. Toi,et al.  Association of Vascular Endothelial Growth Factor Expression with Tumor Angiogenesis and with Early Relapse in Primary Breast Cancer , 1994, Japanese journal of cancer research : Gann.

[76]  A. Giaccia,et al.  Oncogenic transformation and hypoxia synergistically act to modulate vascular endothelial growth factor expression. , 1996, Cancer research.

[77]  Hung V. Nguyen,et al.  The Carboxyl-terminal Domain(111165) of Vascular Endothelial Growth Factor Is Critical for Its Mitogenic Potency (*) , 1996, The Journal of Biological Chemistry.

[78]  R. Kendall,et al.  Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[79]  N. Ferrara,et al.  Differential Transcriptional Regulation of the Two Vascular Endothelial Growth Factor Receptor Genes , 1997, The Journal of Biological Chemistry.

[80]  B. Keyt,et al.  Solution structure of the heparin-binding domain of vascular endothelial growth factor. , 1998, Structure.

[81]  M. Persico Placenta Growth Factor , 2001 .

[82]  L. Jingjing,et al.  Human Müller cells express VEGF183, a novel spliced variant of vascular endothelial growth factor. , 1999, Investigative ophthalmology & visual science.

[83]  P. Sun,et al.  The cystine-knot growth-factor superfamily. , 1995, Annual review of biophysics and biomolecular structure.

[84]  M. Merrill,et al.  Differential expression of vascular endothelial growth factor (vascular permeability factor) forms in rat tissues. , 1995, Growth factors.

[85]  D. Connolly,et al.  Identification, Purification, and Characterization of Cell-surface Retention Sequence-binding Proteins from Human SK-Hep Cells and Bovine Liver Plasma Membranes (*) , 1995, The Journal of Biological Chemistry.

[86]  L. Williams,et al.  A Novel Promoter for Vascular Endothelial Growth Factor Receptor (flt-1) That Confers Endothelial-specific Gene Expression (*) , 1995, The Journal of Biological Chemistry.

[87]  K. Alitalo,et al.  Cardiovascular failure in mouse embryos deficient in VEGF receptor-3. , 1998, Science.

[88]  Shay Soker,et al.  Characterization of Novel Vascular Endothelial Growth Factor (VEGF) Receptors on Tumor Cells That Bind VEGF via Its Exon 7-encoded Domain (*) , 1996, The Journal of Biological Chemistry.

[89]  D. Hicklin,et al.  Heparin modulates the interaction of VEGF165 with soluble and cell associated flk-1 receptors. , 1994, The Journal of biological chemistry.

[90]  D. Hanahan,et al.  Switch to the angiogenic phenotype during tumorigenesis. , 1991, Princess Takamatsu symposia.

[91]  G. Semenza,et al.  Hypoxia-inducible factor 1 levels vary exponentially over a physiologically relevant range of O2 tension. , 1996, The American journal of physiology.

[92]  J. Gallagher,et al.  Molecules in focus: heparan sulphate , 1997 .

[93]  Shu-Yun Le,et al.  Regulation of vascular endothelial growth factor (VEGF) expression is mediated by internal initiation of translation and alternative initiation of transcription , 1998, Oncogene.

[94]  G. Breier,et al.  The Vascular Endothelial Growth Factor Receptor Flt-1 Mediates Biological Activities , 1996, The Journal of Biological Chemistry.

[95]  D. Goeddel,et al.  Vascular endothelial growth factor is a secreted angiogenic mitogen. , 1989, Science.

[96]  G. Neufeld,et al.  Platelet Factor-4 Inhibits the Mitogenic Activity of VEGF121 and VEGF165 Using Several Concurrent Mechanisms (*) , 1995, The Journal of Biological Chemistry.

[97]  W. Wood,et al.  Vascular endothelial growth factor-related protein: a ligand and specific activator of the tyrosine kinase receptor Flt4. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[98]  U. Hellman,et al.  Differential Binding of Vascular Endothelial Growth Factor B Splice and Proteolytic Isoforms to Neuropilin-1* , 1999, The Journal of Biological Chemistry.

[99]  P. Gleizes,et al.  Cell Release of Bioactive Fibroblast Growth Factor 2 by Exon 6-encoded Sequence of Vascular Endothelial Growth Factor* , 1997, The Journal of Biological Chemistry.

[100]  S. Soker,et al.  Vascular endothelial growth factor is inactivated by binding to alpha 2-macroglobulin and the binding is inhibited by heparin. , 1993, The Journal of biological chemistry.

[101]  T. Veikkola,et al.  Vascular endothelial growth factor (VEGF)-like protein from orf virus NZ2 binds to VEGFR2 and neuropilin-1. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[102]  V. Hombach,et al.  Functional upregulation of the vascular endothelial growth factor receptor KDR by hypoxia. , 1996, Circulation.

[103]  M. Rocchi,et al.  Assignment of the vascular endothelial growth factor gene to human chromosome 6p21.3. , 1996, Circulation.

[104]  G. Martiny-Baron,et al.  VEGF121 induces proliferation of vascular endothelial cells and expression of flk-1 without affecting lymphatic vessels of chorioallantoic membrane. , 1996, Developmental biology.

[105]  E. Bauer,et al.  Vascular endothelial growth factor induces interstitial collagenase expression in human endothelial cells , 1992, Journal of cellular physiology.

[106]  L. Aiello,et al.  Comparative Analysis of Vascular Endothelial Growth Factor Receptors on Retinal and Aortic Vascular Endothelial Cells , 1995, Diabetes.

[107]  D. Mukhopadhyay,et al.  The von Hippel-Lindau tumor suppressor gene product interacts with Sp1 to repress vascular endothelial growth factor promoter activity , 1997, Molecular and cellular biology.

[108]  K. Alitalo,et al.  Comparison of VEGF, VEGF-B, VEGF-C and Ang-1 mRNA regulation by serum, growth factors, oncoproteins and hypoxia , 1997, Oncogene.

[109]  K. Alitalo,et al.  Signaling via vascular endothelial growth factor receptors. , 1999, Experimental cell research.

[110]  D. Connolly,et al.  Human vascular permeability factor. Isolation from U937 cells. , 1989, The Journal of biological chemistry.

[111]  L. Aiello,et al.  Adenosine mediates hypoxic induction of vascular endothelial growth factor in retinal pericytes and endothelial cells. , 1996, Investigative ophthalmology & visual science.

[112]  G. Lundborg,et al.  Vascular Endothelial Growth Factor Has Neurotrophic Activity and Stimulates Axonal Outgrowth, Enhancing Cell Survival and Schwann Cell Proliferation in the Peripheral Nervous System , 1999, The Journal of Neuroscience.

[113]  J. Peng,et al.  Increased hemangioblast commitment, not vascular disorganization, is the primary defect in flt-1 knock-out mice. , 1999, Development.

[114]  G. Martiny-Baron,et al.  An antagonistic vascular endothelial growth factor (VEGF) variant inhibits VEGF-stimulated receptor autophosphorylation and proliferation of human endothelial cells. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[115]  L. Kjellén,et al.  Regulated Diversity of Heparan Sulfate* , 1998, The Journal of Biological Chemistry.

[116]  R. Kendall,et al.  Identification of a natural soluble form of the vascular endothelial growth factor receptor, FLT-1, and its heterodimerization with KDR. , 1996, Biochemical and biophysical research communications.

[117]  A Shinkai,et al.  Mapping of the Sites Involved in Ligand Association and Dissociation at the Extracellular Domain of the Kinase Insert Domain-containing Receptor for Vascular Endothelial Growth Factor* , 1998, The Journal of Biological Chemistry.

[118]  J. Schneider-Mergener,et al.  Vascular Endothelial Growth Factor (VEGF) Receptor II-derived Peptides Inhibit VEGF* , 1999, The Journal of Biological Chemistry.

[119]  K. Alitalo,et al.  Vascular endothelial growth factor B, a novel growth factor for endothelial cells. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[120]  E. Keshet,et al.  Conditional switching of vascular endothelial growth factor (VEGF) expression in tumors: induction of endothelial cell shedding and regression of hemangioblastoma-like vessels by VEGF withdrawal. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[121]  R. Kendall,et al.  Specificity of vascular endothelial cell growth factor receptor ligand binding domains. , 1994, Biochemical and biophysical research communications.

[122]  W. Kolch,et al.  Mutant p53 potentiates protein kinase C induction of vascular endothelial growth factor expression. , 1994, Oncogene.

[123]  D. Merberg,et al.  Molecular cloning of murine FLT and FLT4. , 1993, Oncogene.

[124]  G. Conn,et al.  Purification and Characterization of a Naturally Occurring Vascular Endothelial Growth Factor · Placenta Growth Factor Heterodimer (*) , 1995, The Journal of Biological Chemistry.

[125]  L. Williams,et al.  Vascular endothelial growth factor receptor expression during embryogenesis and tissue repair suggests a role in endothelial differentiation and blood vessel growth. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[126]  V. Praloran,et al.  [Mitogenic activity of vasculotropin for peripheral human lymphocytes]. , 1991, Comptes rendus de l'Academie des sciences. Serie III, Sciences de la vie.

[127]  M. Shibuya,et al.  Neuropilin-1 Is a Placenta Growth Factor-2 Receptor* , 1998, The Journal of Biological Chemistry.

[128]  N. Sheibani,et al.  Down-regulation of platelet endothelial cell adhesion molecule-1 results in thrombospondin-1 expression and concerted regulation of endothelial cell phenotype. , 1998, Molecular biology of the cell.

[129]  G. Martiny-Baron,et al.  Vascular endothelial growth factor up-regulates its receptor fms-like tyrosine kinase 1 (FLT-1) and a soluble variant of FLT-1 in human vascular endothelial cells. , 1997, Cancer research.

[130]  E. Haber,et al.  Cloning and Functional Analysis of the Promoter for KDR/flk-1, a Receptor for Vascular Endothelial Growth Factor(*) , 1995, The Journal of Biological Chemistry.

[131]  Ulf Eriksson,et al.  Vascular endothelial growth factors VEGF‐B and VEGF‐C , 1997, Journal of cellular physiology.

[132]  B Z Levi,et al.  VEGF121, a vascular endothelial growth factor (VEGF) isoform lacking heparin binding ability, requires cell-surface heparan sulfates for efficient binding to the VEGF receptors of human melanoma cells , 1995, The Journal of Biological Chemistry.

[133]  D. Gospodarowicz,et al.  Isolation and characterization of a vascular endothelial cell mitogen produced by pituitary-derived folliculo stellate cells. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[134]  P. Romeo,et al.  Neuropilin-1 is expressed on bone marrow stromal cells: a novel interaction with hematopoietic cells? , 1999, Blood.

[135]  D. Dimitrov,et al.  Identification of the KDR tyrosine kinase as a receptor for vascular endothelial cell growth factor. , 1992, Biochemical and biophysical research communications.

[136]  S. Soker,et al.  Tumor Necrosis Factor-α Regulates Expression of Vascular Endothelial Growth Factor Receptor-2 and of Its Co-receptor Neuropilin-1 in Human Vascular Endothelial Cells* , 1998, The Journal of Biological Chemistry.

[137]  J. Isner,et al.  Vascular endothelial growth factor-C (VEGF-C/VEGF-2) promotes angiogenesis in the setting of tissue ischemia. , 1998, The American journal of pathology.

[138]  A. Mantovani,et al.  Migration of human monocytes in response to vascular endothelial growth factor (VEGF) is mediated via the VEGF receptor flt-1. , 1996, Blood.

[139]  T. Kitsukawa,et al.  Developmentally regulated expression of a cell surface protein, neuropilin, in the mouse nervous system. , 1996, Journal of neurobiology.

[140]  Janet Rossant,et al.  Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice , 1995, Nature.

[141]  J. Caro,et al.  Absolute requirement of aryl hydrocarbon receptor nuclear translocator protein for gene activation by hypoxia. , 1996, Archives of biochemistry and biophysics.

[142]  K. Igarashi,et al.  Tyrosine 1213 of Flt-1 is a major binding site of Nck and SHP-2. , 1998, Biochemical and biophysical research communications.

[143]  D. Mukhopadhyay,et al.  Wild-type p53 and v-Src exert opposing influences on human vascular endothelial growth factor gene expression. , 1995, Cancer research.

[144]  T. Yagi,et al.  Neuropilin–Semaphorin III/D-Mediated Chemorepulsive Signals Play a Crucial Role in Peripheral Nerve Projection in Mice , 1997, Neuron.

[145]  A. Mercer,et al.  Homologs of vascular endothelial growth factor are encoded by the poxvirus orf virus , 1994, Journal of virology.

[146]  S. Takagi,et al.  Expression of a cell adhesion molecule, neuropilin, in the developing chick nervous system. , 1995, Developmental biology.

[147]  K. Alitalo,et al.  FLT4 receptor tyrosine kinase contains seven immunoglobulin-like loops and is expressed in multiple human tissues and cell lines. , 1992, Cancer research.

[148]  T. Blundell,et al.  Topological similarities in TGF-beta 2, PDGF-BB and NGF define a superfamily of polypeptide growth factors. , 1993, Structure.

[149]  R. Jain,et al.  Hyperplasia of lymphatic vessels in VEGF-C transgenic mice. , 1997, Science.

[150]  G. Sachs,et al.  Two Functional Forms of Vascular Endothelial Growth Factor Receptor-2/Flk-1 mRNA Are Expressed in Normal Rat Retina* , 1998, The Journal of Biological Chemistry.

[151]  A. Karsan,et al.  Signaling pathways induced by vascular endothelial growth factor (review). , 2000, International journal of molecular medicine.

[152]  L. Brown,et al.  VEGF, flk-1, and flt-1 expression in a rat myocardial infarction model of angiogenesis. , 1996, The American journal of physiology.

[153]  J. Folkman,et al.  Angiogenesis and angiogenesis inhibition: an overview. , 1997, EXS.

[154]  E. Keshet,et al.  Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis , 1992, Nature.

[155]  K. Dutt,et al.  Vasculotropin/Vascular endothelial growth factor is an autocrine growth factor for human retinal pigment epithelial cells cultued in vitro , 1995, Journal of cellular physiology.

[156]  A. Ullrich,et al.  High affinity VEGF binding and developmental expression suggest Flk-1 as a major regulator of vasculogenesis and angiogenesis , 1993, Cell.

[157]  Alex L Kolodkin,et al.  Neuropilin Is a Semaphorin III Receptor , 1997, Cell.

[158]  M. Shibuya,et al.  Nucleotide sequence and expression of a novel human receptor-type tyrosine kinase gene (flt) closely related to the fms family. , 1990, Oncogene.

[159]  G. Neufeld,et al.  Glypican-1 Is a VEGF165 Binding Proteoglycan That Acts as an Extracellular Chaperone for VEGF165 * , 1999, The Journal of Biological Chemistry.

[160]  Alex L Kolodkin,et al.  Neuropilin-2 Is a Receptor for Semaphorin IV Insight into the Structural Basis of Receptor Function and Specificity , 1998, Neuron.

[161]  D. Connolly,et al.  Regulation of hexose transport in aortic endothelial cells by vascular permeability factor and tumor necrosis factor-alpha, but not by insulin. , 1990, The Journal of biological chemistry.

[162]  D. Gospodarowicz,et al.  Glycosylation of vascular endothelial growth factor is not required for its mitogenic activity. , 1992, Biochemical and biophysical research communications.

[163]  M. Shibuya,et al.  A Novel Type of Vascular Endothelial Growth Factor, VEGF-E (NZ-7 VEGF), Preferentially Utilizes KDR/Flk-1 Receptor and Carries a Potent Mitotic Activity without Heparin-binding Domain* , 1998, The Journal of Biological Chemistry.

[164]  S. Soker,et al.  Selective Binding of VEGF to One of the Three Vascular Endothelial Growth Factor Receptors of Vascular Endothelial Cells (*) , 1996, The Journal of Biological Chemistry.

[165]  L. Presta,et al.  The second immunoglobulin‐like domain of the VEGF tyrosine kinase receptor Flt‐1 determines ligand binding and may initiate a signal transduction cascade. , 1996, The EMBO journal.

[166]  D. Charnock-Jones,et al.  Alternative splicing of vascular endothelial growth factor (VEGF)-R1 (FLT-1) pre-mRNA is important for the regulation of VEGF activity. , 1999, Molecular endocrinology.

[167]  Yihai Cao,et al.  Placenta growth factor stimulates MAP kinase and mitogenicity but not phospholipase C-γ and migration of endothelial cells expressing Flt 1 , 1998, Oncogene.

[168]  A. Levy,et al.  Hypoxic Stabilization of Vascular Endothelial Growth Factor mRNA by the RNA-binding Protein HuR* , 1998, The Journal of Biological Chemistry.

[169]  K. Plate,et al.  Putative Control of Angiogenesis in Hemangioblastomas by the von Hippel‐Lindau Tumor Suppressor Gene , 1997, Journal of neuropathology and experimental neurology.

[170]  K. Alitalo,et al.  VEGF-C receptor binding and pattern of expression with VEGFR-3 suggests a role in lymphatic vascular development. , 1996, Development.

[171]  J. Winer,et al.  Placenta growth factor. Potentiation of vascular endothelial growth factor bioactivity, in vitro and in vivo, and high affinity binding to Flt-1 but not to Flk-1/KDR. , 1994, The Journal of biological chemistry.

[172]  R. Eddy,et al.  Identification of a new endothelial cell growth factor receptor tyrosine kinase. , 1991, Oncogene.

[173]  J. Isner,et al.  Synergistic effect of vascular endothelial growth factor and basic fibroblast growth factor on angiogenesis in vivo. , 1995, Circulation.

[174]  J. Rossant,et al.  Role of the Flt-1 receptor tyrosine kinase in regulating the assembly of vascular endothelium , 1995, Nature.

[175]  J. Keiser,et al.  Vascular endothelial growth factor upregulates the expression of matrix metalloproteinases in vascular smooth muscle cells: role of flt-1. , 1998, Circulation research.

[176]  V. Vincenti,et al.  Structure, expression and receptor-binding properties of placenta growth factor (PlGF). , 1999, Current topics in microbiology and immunology.

[177]  N. Ferrara,et al.  The biology of vascular endothelial growth factor. , 1997, Endocrine reviews.

[178]  Kenneth J. Hillan,et al.  Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene , 1996, Nature.

[179]  S. Kaul,et al.  A Novel Alternatively Spliced Form of Murine Vascular Endothelial Growth Factor, VEGF 115* , 1998, The Journal of Biological Chemistry.

[180]  P. Nawroth,et al.  Regulation of vascular endothelial growth factor production and angiogenesis by the cytoplasmic tail of tissue factor. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[181]  T. Quinn,et al.  Fetal liver kinase 1 is a receptor for vascular endothelial growth factor and is selectively expressed in vascular endothelium. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[182]  D. Marmé,et al.  Both v-Ha-Ras and v-Raf Stimulate Expression of the Vascular Endothelial Growth Factor in NIH 3T3 Cells (*) , 1995, The Journal of Biological Chemistry.

[183]  J. Caro,et al.  Hypoxic stimulation of vascular endothelial growth factor expression in vitro and in vivo. , 1994, Laboratory investigation; a journal of technical methods and pathology.

[184]  J. Flanagan,et al.  Heterodimers of Placenta Growth Factor/Vascular Endothelial Growth Factor , 1996, The Journal of Biological Chemistry.

[185]  S. Mandriota,et al.  Regulation of vascular endothelial growth factor receptor-2 (Flk-1) expression in vascular endothelial cells. , 1998, Experimental cell research.

[186]  P. Einat,et al.  Translation of Vascular Endothelial Growth Factor mRNA by Internal Ribosome Entry: Implications for Translation under Hypoxia , 1998, Molecular and Cellular Biology.

[187]  D. Maglione Persico MG.Isolation of a human placenta cDNA coding for a potein related to the vascular premeability factor , 1991 .

[188]  N. Copeland,et al.  A receptor tyrosine kinase cDNA isolated from a population of enriched primitive hematopoietic cells and exhibiting close genetic linkage to c-kit. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[189]  B. Keyt,et al.  The crystal structure of vascular endothelial growth factor (VEGF) refined to 1.93 A resolution: multiple copy flexibility and receptor binding. , 1997, Structure.

[190]  B. Spiegelman,et al.  Vascular endothelial growth factor. Regulation by cell differentiation and activated second messenger pathways. , 1992, The Journal of biological chemistry.

[191]  G. Viglietto,et al.  Two alternative mRNAs coding for the angiogenic factor, placenta growth factor (PlGF), are transcribed from a single gene of chromosome 14. , 1993, Oncogene.

[192]  P. Curtin,et al.  A 24-base-pair sequence 3' to the human erythropoietin gene contains a hypoxia-responsive transcriptional enhancer. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[193]  S. Kourembanas,et al.  Hypoxia regulates vascular endothelial growth factor gene expression in endothelial cells. Identification of a 5' enhancer. , 1995, Circulation research.

[194]  F. Bayard,et al.  Extracellular Cleavage of the Vascular Endothelial Growth Factor 189-Amino Acid Form by Urokinase Is Required for Its Mitogenic Effect* , 1997, The Journal of Biological Chemistry.

[195]  C. Heldin,et al.  Identification of a 190-kDa Vascular Endothelial Growth Factor 165 Cell Surface Binding Protein on a Human Glioma Cell Line* , 1997, The Journal of Biological Chemistry.

[196]  D. Gospodarowicz,et al.  Isolation and characterization of a newly identified endothelial cell mitogen produced by AtT‐20 cells. , 1989, The EMBO journal.

[197]  S. Soker,et al.  Tumor necrosis factor-alpha regulates expression of vascular endothelial growth factor receptor-2 and of its co-receptor neuropilin-1 in human vascular endothelial cells. , 1998, The Journal of biological chemistry.

[198]  M. A. Pickett,et al.  Short report: identification of a specific pattern of vascular endothelial growth factor mRNA expression in human placenta and cultured placental fibroblasts. , 1994, Placenta.

[199]  D. Ruiter,et al.  Covalent dimerization of vascular permeability factor/vascular endothelial growth factor is essential for its biological activity. Evidence from Cys to Ser mutations. , 1994, The Journal of biological chemistry.

[200]  F. Piehl,et al.  Restricted expression pattern of vegf-d in the adult and fetal mouse: high expression in the embryonic lung. , 1999, Biochemical and biophysical research communications.

[201]  J. Fiddes,et al.  The human gene for vascular endothelial growth factor. Multiple protein forms are encoded through alternative exon splicing. , 1991, The Journal of biological chemistry.

[202]  D. Mukhopadhyay,et al.  The von Hippel-Lindau Gene Product Inhibits Vascular Permeability Factor/Vascular Endothelial Growth Factor Expression in Renal Cell Carcinoma by Blocking Protein Kinase C Pathways* , 1997, The Journal of Biological Chemistry.

[203]  J. Flanagan,et al.  Interactions between the Flk-1 receptor, vascular endothelial growth factor, and cell surface proteoglycan identified with a soluble receptor reagent. , 1995, Growth factors.

[204]  M. Shibuya,et al.  The 230 kDa mature form of KDR/Flk-1 (VEGF receptor-2) activates the PLC-γ pathway and partially induces mitotic signals in NIH3T3 fibroblasts , 1997, Oncogene.